- Bio-Path BPTH shares are trading higher Wednesday after the company announced it received a third U.S. patent grant related to the manufacture of its platform technology.
- Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease.
- Bio-Path shares traded up 150.19% to $13.01 at the time of publication. The stock has a 52-week high of $24.34 and a 52-week low of $2.92.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in